What is the role of sodium bicarbonate in patients with hepatic encephalopathy and acute kidney injury?

Sodium Bicarbonate Has No Established Role in Hepatic Encephalopathy with AKI

Sodium bicarbonate should not be routinely administered to patients with hepatic encephalopathy and acute kidney injury, as there is no evidence supporting its use in this specific population and it may cause harm through sodium/fluid overload and worsening of hepatic encephalopathy.

Clinical Context and Rationale

The question addresses two distinct pathophysiologic processes occurring simultaneously—hepatic encephalopathy (HE) and AKI in cirrhotic patients. While sodium bicarbonate has defined indications in certain clinical scenarios, its role in this specific combination requires careful analysis.

Why Bicarbonate is NOT Indicated

In Hepatic Encephalopathy:

• No guideline or evidence supports bicarbonate use for HE management 1, 2, 3
• Standard HE treatment focuses on lactulose, rifaximin, and ammonia-lowering strategies 1
• Sodium loading from bicarbonate can worsen ascites and fluid retention, potentially precipitating or worsening HE 4
• Cirrhotic patients already have impaired sodium handling and are prone to volume overload

In AKI with Cirrhosis:

• The 2017 Surviving Sepsis Guidelines recommend against sodium bicarbonate for lactic acidemia with pH ≥7.15, citing lack of hemodynamic benefit and risks of sodium/fluid overload, increased lactate, and decreased ionized calcium 5
• The most recent 2025 BICARICU-2 trial showed no mortality benefit from bicarbonate in patients with severe metabolic acidemia (pH ≤7.20) and moderate-to-severe AKI 6
• A 2019 marginal structural Cox model analysis found no overall mortality benefit from bicarbonate in AKI with acidosis, though potential benefit existed in severe acidosis (pH <7.15) subgroups 7

When Bicarbonate MIGHT Be Considered (Specific Scenarios Only)

Renal Replacement Therapy Context: If the patient requires RRT, the KDIGO guidelines recommend using bicarbonate-based dialysate/replacement fluid rather than lactate-based solutions, particularly in:

• Patients with liver failure and/or lactic acidemia (Grade 2B recommendation) 8
• Patients with circulatory shock (Grade 1B recommendation) 8

This is fundamentally different from administering IV sodium bicarbonate—it refers to the buffer composition of dialysis fluids.

Severe Metabolic Acidosis (pH <7.15):

• Limited evidence suggests potential benefit in severe acidosis with AKI 7, 9
• However, the 2025 BICARICU-2 trial contradicts this, showing no mortality benefit even at pH ≤7.20 6
• If considered at pH <7.15, administer as slow IV infusion (not bolus) with adequate ventilation to eliminate CO2 9

Critical Pitfalls to Avoid

1. Sodium and Fluid Overload: Cirrhotic patients are exquisitely sensitive to sodium loading. Bicarbonate administration can precipitate or worsen ascites, edema, and potentially trigger HE through volume expansion 5, 4

2. Worsening Encephalopathy: Increased sodium load and fluid shifts may worsen cerebral edema and HE severity

3. Metabolic Consequences: Bicarbonate causes:

   • Paradoxical increase in lactate production 5
   • Decreased ionized calcium (problematic in liver disease with coagulopathy) 5
   • Increased PaCO2 (requires adequate ventilation) 5

4. False Reassurance: Correcting pH without addressing underlying pathology (hepatorenal syndrome, sepsis, hypovolemia) provides no clinical benefit 10, 9

Appropriate Management Algorithm

For HE with AKI:

1. Identify and treat precipitants: infection (SBP), GI bleeding, hypovolemia, nephrotoxins, electrolyte disturbances
2. Standard HE management: lactulose (2-3 soft stools/day), rifaximin 550 mg BID 1
3. AKI-specific interventions:
   • Discontinue diuretics if appropriate 4
   • Volume resuscitation with albumin if hypovolemic
   • Treat hepatorenal syndrome with terlipressin/albumin or midodrine/octreotide if indicated 11
4. Consider RRT only for standard indications: refractory volume overload, severe hyperkalemia, uremia, or as bridge to transplant 11
   • If RRT initiated, use bicarbonate-based (not lactate-based) dialysate 8

Bicarbonate administration should be reserved ONLY for:

• Documented severe metabolic acidosis (pH <7.15) with hemodynamic instability, AND only after optimizing ventilation
• Specific toxicologic indications (not applicable here)
• As dialysate buffer during RRT (not IV administration)

Evidence Quality Assessment

The strongest evidence against routine bicarbonate use comes from:

• 2025 BICARICU-2 RCT (640 patients, pH ≤7.20 with AKI): no mortality benefit 6
• 2017 Surviving Sepsis Guidelines (moderate quality evidence): recommend against use at pH ≥7.15 5
• KDIGO AKI Guidelines: bicarbonate-based dialysate preferred over lactate in liver failure during RRT 8

The evidence is clear: routine sodium bicarbonate administration in hepatic encephalopathy with AKI is not beneficial and potentially harmful. Focus on treating the underlying causes of both conditions rather than attempting pH correction.